The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours Journal Article


Authors: Mcguire, M. S.; Rabbani, F.; Mohseni, H.; Bains, M.; Motzer, R.; Sheinfeld, J.
Article Title: The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours
Abstract: OBJECTIVE: To evaluate the clinical outcome and identify prognostic variables in patients with nonseminomatous germ cell tumours undergoing postchemotherapy thoracotomy for residual masses, as the role of this procedure is controversial. PATIENTS AND METHODS: Of 385 patients who underwent postchemotherapy retroperitoneal lymph node dissections between 1988 and 1998, 105 also had 130 thoracotomies. The clinical presentation, chemotherapy regimens, marker status, primary tumour histology, pathology of all resected masses, and clinical outcome of these 105 patients were analysed. RESULTS: The overall discordance rate for synchronous thoracic and retroperitoneal masses was 28%; that for asynchronous thoracic and retroperitoneal masses was 57%. Independent prognostic factors for residual thoracic teratoma or cancer were teratoma (mature or immature) in the primary tumour or retroperitoneal teratoma or cancer. Although three of 12 patients with residual thoracic cancer remained with no evidence of disease, residual thoracic cancer is an independent prognostic factor (P < 0.001) against disease-free survival. CONCLUSION: Postchemotherapy thoracotomy yields important prognostic information, and is therapeutic for most patients with teratoma and a subset with residual viable cancer. The prognostic criteria predictive of fibrosis are not sufficiently accurate to omit resection of residual thoracic masses.
Keywords: cancer chemotherapy; treatment outcome; disease-free survival; major clinical study; cancer localization; cancer recurrence; cancer risk; cancer patient; follow-up studies; disease association; carboplatin; etoposide; thoracotomy; antineoplastic combined chemotherapy protocols; odds ratio; obesity; tumor biopsy; oncology; ifosfamide; vinblastine; risk assessment; prostate cancer; thoracic neoplasms; evaluation; prostatectomy; testicular neoplasms; bleomycin; outcomes research; platinum; testis cancer; germ cell tumor; thorax tumor; non seminomatous germinoma; germinoma; humans; prognosis; human; male; priority journal; article; nonseminomatous germ cell cancer
Journal Title: BJU International
Volume: 91
Issue: 6
ISSN: 1464-4096
Publisher: Wiley Blackwell  
Date Published: 2003-04-01
Start Page: 469
End Page: 473
Language: English
DOI: 10.1046/j.1464-410X.2003.04128.x
PUBMED: 12656895
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 12 September 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. Farhang Rabbani
    84 Rabbani
  3. Joel Sheinfeld
    254 Sheinfeld
  4. Manjit S Bains
    338 Bains